These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 39059249)
1. Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-α agonists. Li L; Yang C; Qiao X; Yang X; Zhang J; Cui M; Li Z; Tian A; Li X; Zou X; Li Y; He W; Chen Y; He X Bioorg Med Chem; 2024 Sep; 111():117845. PubMed ID: 39059249 [TBL] [Abstract][Full Text] [Related]
2. The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock. Ishimaru K; Nakajima S; Yu G; Nakamura Y; Nakao A Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847374 [TBL] [Abstract][Full Text] [Related]
3. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy. Shen W; Zhang W; Ye W; Wang H; Zhang Q; Shen J; Hong Q; Li X; Wen G; Wei T; Zhang J Theranostics; 2020; 10(10):4466-4480. PubMed ID: 32292508 [No Abstract] [Full Text] [Related]
4. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation. Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617 [TBL] [Abstract][Full Text] [Related]
6. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Dierickx P; Emmett MJ; Jiang C; Uehara K; Liu M; Adlanmerini M; Lazar MA Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12147-12152. PubMed ID: 31127047 [TBL] [Abstract][Full Text] [Related]
7. REV-ERB Agonist SR9009 Regulates the Proliferation and Neurite Outgrowth/Suppression of Cultured Rat Adult Hippocampal Neural Stem/Progenitor Cells in a Concentration-Dependent Manner. Shimozaki K Cell Mol Neurobiol; 2022 Aug; 42(6):1765-1776. PubMed ID: 33599915 [TBL] [Abstract][Full Text] [Related]
8. Stimulation of nuclear receptor REV-ERBs suppresses production of pronociceptive molecules in cultured spinal astrocytes and ameliorates mechanical hypersensitivity of inflammatory and neuropathic pain of mice. Morioka N; Kodama K; Tomori M; Yoshikawa K; Saeki M; Nakamura Y; Zhang FF; Hisaoka-Nakashima K; Nakata Y Brain Behav Immun; 2019 May; 78():116-130. PubMed ID: 30682503 [TBL] [Abstract][Full Text] [Related]
9. Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism. Stujanna EN; Murakoshi N; Tajiri K; Xu D; Kimura T; Qin R; Feng D; Yonebayashi S; Ogura Y; Yamagami F; Sato A; Nogami A; Aonuma K PLoS One; 2017; 12(12):e0189330. PubMed ID: 29232411 [TBL] [Abstract][Full Text] [Related]
10. REV-ERB agonist suppresses IL-17 production in γδT cells and improves psoriatic dermatitis in a mouse model. Wang S; Kozai M; Mita H; Cai Z; Masum MA; Ichii O; Takada K; Inaba M Biomed Pharmacother; 2021 Dec; 144():112283. PubMed ID: 34628169 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression. Amador A; Wang Y; Banerjee S; Kameneka TM; Solt LA; Burris TP PLoS One; 2016; 11(3):e0151014. PubMed ID: 26963516 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Sulli G; Rommel A; Wang X; Kolar MJ; Puca F; Saghatelian A; Plikus MV; Verma IM; Panda S Nature; 2018 Jan; 553(7688):351-355. PubMed ID: 29320480 [TBL] [Abstract][Full Text] [Related]
13. Rev-erbα activation down-regulates hepatic Pck1 enzyme to lower plasma glucose in mice. Yuan X; Dong D; Li Z; Wu B Pharmacol Res; 2019 Mar; 141():310-318. PubMed ID: 30639375 [TBL] [Abstract][Full Text] [Related]
14. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. Geldof L; Deventer K; Roels K; Tudela E; Van Eeno P Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706103 [TBL] [Abstract][Full Text] [Related]
16. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Xu H; Zhang J; Zheng X; Tan P; Xiong X; Yi X; Yang Y; Wang Y; Liao D; Li H; Wei Q; Ai J; Yang L Cell Death Dis; 2022 Nov; 13(11):949. PubMed ID: 36357378 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease. Roby DA; Ruiz F; Kermath BA; Voorhees JR; Niehoff M; Zhang J; Morley JE; Musiek ES; Farr SA; Burris TP PLoS One; 2019; 14(4):e0215004. PubMed ID: 30973894 [TBL] [Abstract][Full Text] [Related]
19. REV-ERBα agonist SR9009 suppresses IL-1β production in macrophages through BMAL1-dependent inhibition of inflammasome. Hong H; Cheung YM; Cao X; Wu Y; Li C; Tian XY Biochem Pharmacol; 2021 Oct; 192():114701. PubMed ID: 34324866 [TBL] [Abstract][Full Text] [Related]
20. REV-ERBs negatively regulate mineralization of the cementoblasts. Fu L; Wang M; Zhu G; Zhao Z; Sun H; Cao Z; Xia H Biochem Biophys Res Commun; 2022 Jan; 587():9-15. PubMed ID: 34861472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]